Fundraising Fox

Immusoft

Seattle, US · Delaware corporation · 8 known investors

immusoft.com ↗

Immusoft develops novel therapeutic treatments by programming B cells to produce therapeutic proteins for patients with rare and other diseases with significant unmet medical need. The company uses its Immune System Programming platform to modify B cells to secrete therapeutic proteins.

Biotech

Founders & leadership

MS
Matthew ScholzFounder
MA
Mark Ahn, Ph.D.Director
SA
Sean AinsworthChief Executive Officer

Investors · 8

BioRock VenturesSan Francisco
Boston Harbor AngelsBoston · $250K – $1.5M
Breakout VenturesSan Francisco · $500K – $6M
EQx FundBoston
Invariantes FundGuatemala City
Michigan Capital NetworkGrand Rapids
NYBC VenturesNew York
NYBC Venturesreported

Reported raises · per SEC filings

Form D private placements
▶$4.6MraisedJun 2024 · 25 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Julia MooreDirector
  • Sean AinsworthExecutive Officer, Director
  • Matthew ScholzDirector
  • Cam GallahgerDirector
  • Anthony SunDirector
Offering amount
$10M
Amount sold
$4.6M
First sale
May 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$10.3MraisedMar 2021 · 32 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Anthony SunDirector
  • Julia MooreDirector
  • Wendell KingDirector
  • Sean c/o AinsworthExecutive Officer, Director
  • Matthew ScholzDirector
Offering amount
$11M
Amount sold
$10.3M
First sale
Sep 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$20.2MraisedJan 2019 · 64 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Sean AinsworthExecutive Officer, Director
  • Julia MooreDirector
  • Wendell KingDirector
  • Anthony SunDirector
  • Matthew ScholzDirector
  • Rich VincentExecutive Officer
Offering amount
$23.4M
Amount sold
$20.2M
First sale
Jan 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.7MraisedNov 2016 · 11 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark Ahn, Ph.D.Director
  • Wendell KingDirector
  • Matthew ScholzExecutive Officer, Director
Offering amount
$4.6M
Amount sold
$2.7M
First sale
Oct 2016
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$375KraisedAug 2015 · 3 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Matthew ScholzExecutive Officer, Director
  • Mark Ahn, Ph.D.Director
Offering amount
$1M
Amount sold
$375K
First sale
Aug 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.